Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit
本文は利用できません。元の情報源をご確認ください。
Zenas' stock sinks in wake of autoimmune phase 3 data despite primary endpoint hit